REGN Q1 2021 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.5B+38.3% YoY

Gross Profit

$2.2B85.2% margin

Operating Income

$1.1B44.0% margin

Net Income

$1.1B44.1% margin

EPS (Diluted)

$10.09

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$669M

Free Cash Flow

$553M

Stock-Based Comp.

$131M

Balance Sheet

Total Assets

$17.8B

Total Liabilities

$5.8B

Stockholders' Equity

$12.0B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$1.8B	+38.3%
Gross Profit	$2.2B	$1.6B	+38.5%
Operating Income	$1.1B	$700M	+58.9%
Net Income	$1.1B	$625M	+78.5%

Revenue Segments

Product

$1.7B68%

Collaboration Revenue

$754M30%

Product and Service, Other

$50M2%